{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '7.1.3.4.5.2 Safety Data Oncology Studies', 'In the oncology program, over 700 subjects were treated with teprotumumab at dose levels', 'ranging from 1 to 27 mg/kg q3W or 1 to 9 kg/mg qW. The safety profile of teprotumumab in', 'these studies was confounded by the poor health of the enrolled subjects (most had late-stage', 'cancers) and the administration of combination therapy (teprotumumab in conjunction with other', 'cytotoxic agents) in some subjects.', '7.1.3.4.5.3 Teprotumumab Material Safety Profile', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 58 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '7.1.3.4.5.5 AEs of Special Interest', 'Following a comprehensive review of the safety data from the oncology studies and that from the', 'TED01RV study, the following AESIs have been identified for the current study:', 'Infusion reactions', 'Hyperglycemia', 'Muscle spasms', 'Diarrhea', '7.1.3.4.5.5.1 Overview and Precautions for AESIs', 'Infusion-Associated Events', 'Infusion-associated AEs were reported for 1 teprotumumab-treated subject (mild facial flushing', 'and warmth with concomitant elevated heart rate and blood pressure and moderate hypertension', 'and tachycardia at the end of the 90-minute observation period after the second infusion). At the', 'third infusion visit, the subject was pre-medicated with diphenhydramine, dexamethasone,', 'famotidine and Tylenol and had a similar reaction prior to the study drug infusion.', 'Monoclonal antibodies may cause infusion-associated symptoms such as fever, chills,', 'hypotension, shortness of breath, skin rash, headache, nausea and/or vomiting. Such reactions', 'typically occur during or shortly after the infusion of mAbs and are usually associated with the', 'first infusion. Their incidence and severity typically decrease with subsequent infusion. Severe', 'infusion-associated reactions might be clinically indistinguishable from anaphylactic reactions.', 'Infusion-associated AEs observed with teprotumumab to date have not been anaphylactic in', 'nature. However, because of the protein nature of teprotumumab and the potential for infusion-', 'associated reactions and hypersensitivity reactions, teprotumumab should be administered in a', 'setting with emergency equipment and staff who are trained to monitor medical situations and', 'respond to emergencies. For the first 3 infusions, subjects should be monitored for any AEs', 'during infusion and for 60 minutes after completion of infusion. For subsequent infusions (the', 'fourth dose and beyond), subjects who have not previously experienced an infusion reaction', 'should be monitored during the infusion and for at least 30 minutes after the infusion.', 'Subjects who exhibit immediate hypersensitivity reactions or infusion-associated reactions', 'during an infusion of teprotumumab should have the infusion interrupted or the infusion rate', 'slowed. Symptomatic treatment (e.g., antipyretics, antihistamines and/or corticosteroids, oxygen,', 'beta-agonists, and IV fluids) should be administered to the subject. Following an immediate', 'hypersensitivity reaction or infusion-associated reaction, vital signs (temperature, blood pressure,', 'pulse, and respiratory rate) should be determined every 5 minutes until stable, and then every', '15 minutes for 2 additional determinations. The infusion may be restarted upon complete', 'resolution of symptoms except in the case of subjects who experience an anaphylactic reaction;', 'these subjects should be removed from the study.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 59 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'In general, the decision to keep a subject on study treatment with teprotumumab should take into', 'consideration potential risks and benefits to the subject. Prior to all future infusions of', 'teprotumumab, these subjects should be pre-medicated with IV diphenhydramine 1 to', '1.25 mg/kg (maximum: 50 mg), IV ranitidine 50 mg, IV dexamethasone 0.4 mg/kg (maximum:', '20 mg), and/or acetaminophen 500 mg. In addition, all future infusions should be administered', 'over approximately 90 minutes (but not less than 80 minutes). Vital signs should be taken every', '15 minutes during the infusion.', 'Subjects who experience delayed-type hypersensitivity reactions (e.g., skin rash) may remain in', 'the study at the discretion of the Investigator, and prior to all future infusions of teprotumumab,', 'should be pre-medicated with the above medications (diphenhydramine, ranitidine,', 'dexamethasone, and/or acetaminophen). Subjects who experience a worsening delayed-type', 'hypersensitivity reaction following repeated infusions of teprotumumab or who have other signs', 'of serum-sickness (e.g., delayed fever, myalgias, arthralgias) may be removed from the study', 'after discussion with the Investigator and Sponsor.', 'Hyperglycemia', 'In preclinical studies, there was no in vitro cross-reactivity of teprotumumab with the insulin', 'receptor. During TED01RV, among non-diabetic subjects, hyperglycemia occurred at', 'comparable rates in both treatment groups and was uniformly Grade 1 and intermittent. Among', 'diabetic subjects, Grade 2 or 3 hyperglycemia occurred in some teprotumumab-treated subjects;', 'this was well-controlled after diabetes medication adjustment. Glycemic control, as assessed by', 'HbAlc, was at baseline levels following the treatment phase for all subjects in the teprotumumab', 'group.', 'Subjects with known controlled diabetes mellitus are allowed to participate in studies with', 'teprotumumab. HbAlc levels should be monitored regularly in these subjects. Investigators are', \"strongly encouraged to adjust their subjects' diabetes management to maintain subjects' HbA1c\", \"levels at 7%. In the event a subject's HbAlc level rises to > 7% while in the study, the\", 'Investigator must determine the risk versus benefit for each subject to remain in the study.', 'Fasting glucose levels (after at least an 8-hour fast) should be tested at Baseline. Hyperglycemia', 'should be promptly investigated and managed. Subjects with recurrent hyperglycemia, defined as', 'a fasting glucose level of moderate intensity (glucose > >160 - 250 mg/dL), will require evaluation', 'for diabetes mellitus (e.g., fasting glucose, glucose tolerance, and HbA1c tests) and appropriate', 'medical management at the discretion of the Investigator.', 'Muscle Spasms', 'During the TED01RV study, muscle spasms were identified in 19% of the subjects receiving', 'teprotumumab versus 5% of those receiving placebo. In the teprotumumab group, 8 subjects had', 'muscle spasms (6 had Grade 1 and 2 had Grade 2); only 2 subjects experienced the event for', 'longer than one week and were treated with muscle relaxants. If possible, avoid medications', 'known to cause muscle spasms or muscle toxicity such as diuretics or statins and evaluate for', 'other causes of muscle spasm such as electrolyte abnormalities and dehydration.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 60 of 117']\n\n###\n\n", "completion": "END"}